Wednesday, 20 January, 2021

Anti-viral remdevisir gets European Union endorsement as first Covid-19 drug

Gilead Is Testing an Inhalable Form of Intravenous Remdesivir Hetero all set to supply 20,000 vials of Covifor pan-India
Gustavo Carr | 29 June, 2020, 12:29

Remdesivir, which is now administered intravenously through infusions, is the only drug that has an emergency use authorization from the U.S. Food and Drug Administration (FDA) to treat COVID-19.

Cipla, in an e-mailed statement, did not provide details on when the treatment, called Cipremi, will be available.

"Remdesivir, our investigational antiviral medicine, is now given to patients intravenously through daily infusions in the hospital", Gilead Sciences said in a statement, adding that the inhaled formulation will be given through a nebulizer, which could potentially allow for easier administration outside the hospital at early stages of the disease.

Gilead's investigational drug, remdesivir, is now administered in hospitals through daily infusions.

The company also said it hoped to start trials in August of an easier-to-use inhaled version of the medicine, which is now administered only intravenously. It is but to be priced within the United States.

California governor declares budget emergency due to COVID-19 pandemic
San Mateo County, for instance, received permission from the state earlier this month to speed up its reopening process. The governor also noted that there has been an increase in the number of young people testing positive for the virus.

European Medicines Agency said that remdesivir is now the first medicine for Covid-19 to be recommended for authorisation in the EU.


Gilead meanwhile says that it needs to do a lot more testing of its antiviral therapy. Among the patients who suffered a tough form of the disease, the time of recovery made 12 days in the remdesivir group, and 18 days in the placebo group.

"The first set of 20,000 vials in two equal lots of 10,000 each, one of which, will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra", said Hetero Company spokesperson.

"Taking into account the available data, the Agency believes that the risks and benefits was positive in patients with pneumonia who need supplemental oxygen, and patients with severe diseases", - said in a statement.

Research on the drug was first started by Gilead in 2009 with research programs for the treatment of hepatitis C (HCV) and respiratory syncytial virus (RSV) and its antiviral profiling was done in 2013 and early 2014-that suggested its broader antiviral potential. Remdesivir has been previously investigated in humans with Ebola and has shown promise in animal models of MERS and SARS, both closely related to the 2019 novel coronavirus, SARS-CoV-2.